SOURCES SOUGHT
A -- Assessment of Potential Substance Abuse Treatment Medications in Nonhuman Primate Models
- Notice Date
- 5/9/2018
- Notice Type
- Sources Sought
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211, MSC 9559, Bethesda, Maryland, 20892-9559, United States
- ZIP Code
- 20892-9559
- Solicitation Number
- NIHDA-2018-00198
- Archive Date
- 6/9/2018
- Point of Contact
- Tracy Cain, Phone: 3014436677
- E-Mail Address
-
tracy.cain@nih.gov
(tracy.cain@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are Small Businesses; HUBZone Small Businesses; Service-Disabled, Veteran-Owned Small Businesses; 8(a) Small Businesses; Veteran-Owned Small Businesses; Woman-Owned Small Businesses; or Small Disadvantaged Businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. PROJECT REQUIREMENTS: The National Institute on Drug Abuse (NIDA) is seeking capability statements from small businesses having in-house capability to provide technical and scientific expertise to determine the effects of compounds in the following paradigms: (1) drug discrimination test in nonhuman primates when tested alone or in combination with cocaine, and (2) self-administration test in nonhuman primates when tested for ability to reduce cocaine self-administration or to be directly self-administered. This project will be utilized by the Division of Therapeutics and Medical Consequences, Addiction Treatment Discovery Program (ATDP), for the purpose of evaluating the efficacy of potential drug abuse treatment medications in non-human primates. Specifically, Rhesus monkeys will be trained in either drug discrimination or self-administration procedures using cocaine or possibly other drugs of abuse. Test compounds will be provided for testing under blinded conditions with information regarding dose, vehicle, and pretreatment time supplied by NIDA. The requirement is to evaluate the effects of the test compound to either substitute or antagonize the discriminative stimulus effects of the training drug, or for its effects on the self-administration dose-effect curve of the training compound using standard protocols to be agreed upon in advance. Standardized, detailed reports with graphs will be prepared and submitted promptly to the program for each compound tested. Approximately five to twelve compounds per year will be tested using drug discrimination procedures, and another five to twelve compounds will be tested using self-administration procedures, as specified by NIDA. The project will provide the Government with a resource to assist in the management of a research portfolio in substance abuse. Information sent should be relevant and specific in the area under consideration, on each of the following qualifications: 1.Have the capability to obtain and maintain a Drug Enforcement Administration (DEA) drug research registration to work with scheduled drugs. 2.Have the capability to determine the efficacy of Addiction Treatment Discovery Program (ATDP) compounds to substitute for the discriminative stimulus effects of cocaine and or to inhibit or antagonize the discriminative stimulus effects of a cocaine injection. 3.Have the capability to determine the efficacy of ATDP test compounds to alter cocaine­ maintained responding (i.e., cocaine self-administration) as compared to food-maintained responding in nonhuman primates (pretreatment protocol), and or to evaluate the efficacy of ATDP compounds to replace cocaine as the drug available for intravenous self-administration (substitution protocol). 4.Have the capability to attend project meetings. 5.Have the capability to maintain a chronological list of compound authorization, receipt, usage, and evaluation, with separate logs for compounds authorized for drug discrimination and self-administration testing. 6.Have the capability to retain, for the duration of this project, all laboratory notebooks (which shall include hard copies of raw data) and any electronic data files generated under this project, as well as all coded ATDP compounds received for evaluation under this project. 7.Have the capability to conduct follow-up studies on compounds with particular promise as clinical candidates for treatment of cocaine dependence. Capability statements must indicate your current DEA registration for working with Schedules II-V controlled substances. All work performed must comply with the NIH guidelines on the care and use of laboratory animals, and the laboratory must be operated according to the FDA's Good Laboratory Practices Program. MANDATORY REQUIREMENTS: In order to handle substances under the Controlled Substances Act of 1970, it is mandatory that the successful Offeror possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. CAPABILITY STATEMENT/INFORMATION SOUGHT: The established NAICS code is 541715. Information submitted should be relevant and specific in the technical area under consideration, on each of the following qualifications: 1) Experience: An outline of previous similar projects, specifically the techniques employed in the areas described above; 2) Personnel: Name, professional qualifications and specific experience in the work requested and knowledge of, and experience in, the field of drug abuse research; 3) Facilities: Availability and description of the facilities and equipment required to conduct this type of work; 4) demonstrated capability to obtain the DEA registrations discussed above. Also, we will consider appropriateness of professional and technical personnel classifications; any other specific and relevant information about this particular area of procurement that would improve our consideration and evaluation of the information presented. Organizations should demonstrate capability to administer and coordinate interrelated tasks in an effective and timely manner. Documentation may include, but is not limited to, government and commercial contracts the organization performed, references (i.e., names, titles, telephone numbers) and any other information serving to document the organization's capability (e.g., awards, commendations, etc.). All capability statements must provide the following: 1) company name and address; 2) point of contact; 3) phone/fax/email; 4) NAICS Code(s); 5) business size and status; 6) capability information in response to the requirement and qualifications identified in this notice; and 7) type of small business your organization classifies itself as (i.e.: Women-Owned, HUBZone, etc.). Written capability statements must be RECEIVED NO LATER THAN May 25, 2018, and mailed to the Contracting Office Address below, Attn: Tracy Cain. Electronic capability statements will be accepted by the primary point of contact. THIS NOTICE IS NOT A REQUEST FOR PROPOSALS. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/NIHDA-2018-00198/listing.html)
- Record
- SN04916449-W 20180511/180509230739-38626413872ee916d185207173475890 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |